Related Experiment Video

Updated: May 16, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Antihypertensive treatment in patients with class 3 obesity

Jens Jordan1, Sam W Boye, Stephanie Le Breton

  • 1Institute of Clinical Pharmacology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany.

Therapeutic Advances in Endocrinology and Metabolism
|November 14, 2012
PubMed

Insights

Patients with class 3 obesity have less blood pressure control with hydrochlorothiazide alone. Combination therapy improved response, but amlodipine showed reduced effectiveness and caused edema in this population.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Class 3 obesity (BMI ≥ 40 kg/m²) is associated with arterial hypertension.
  • Patients with class 3 obesity often show reduced response to antihypertensive medications.
  • Current hypertension guidelines lack specific recommendations for class 3 obesity, with limited clinical trial data.

Purpose of the Study:

  • To evaluate antihypertensive treatment efficacy in patients with class 3 obesity.
  • To compare treatment outcomes between class 3 obesity and class 1/2 obesity.
  • To identify optimal therapeutic strategies for hypertension management in severe obesity.

Main Methods:

  • Post hoc analysis of a prospective clinical trial data.
  • Comparison of blood pressure control in patients with class 3 obesity versus class 1/2 obesity.
  • Assessment of monotherapy (hydrochlorothiazide) and combination therapies (with amlodipine, irbesartan, or aliskiren).

Main Results:

  • Hydrochlorothiazide monotherapy was less effective for blood pressure control in class 3 obesity.
  • Addition of amlodipine, irbesartan, or aliskiren to hydrochlorothiazide improved blood pressure response.
  • Amlodipine combination therapy was less effective and associated with peripheral edema in 19% of class 3 obesity patients.

Conclusions:

  • Class 3 obesity poses unique challenges for hypertension management.
  • Combination therapy offers improved blood pressure control compared to hydrochlorothiazide monotherapy in severe obesity.
  • Careful consideration of drug-specific side effects, such as edema with amlodipine, is crucial in this patient group.
Abstract

Keywords:
aliskirenhypertensionirbesartanmorbid obesityobesityplaceborenin

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.